A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary) ; Bevacizumab; Doxorubicin liposomal; Gemcitabine; Paclitaxel; Topotecan
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms COCOS
- 16 Jul 2024 Planned End Date changed from 30 Jun 2025 to 12 Jul 2025.
- 15 Jul 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.
- 28 Jul 2023 Primary endpoint (Progression-free survival (PFS) (Phase II and Phase III)) has not been met, according to an AstraZeneca media release.